Effects of semaglutide on risk of cardiovascular events across a continuum of cardiovascular risk: combined post hoc analysis of the SUSTAIN and PIONEER trials

BACKGROUND: Semaglutide is a glucagon-like peptide-1 (GLP-1) analog treatment for type 2 diabetes (T2D) available in subcutaneous (s.c.) and oral formulations. Two cardiovascular (CV) outcomes trials showed that in subjects with T2D at high risk of CV events there were fewer major adverse CV events...

Full description

Saved in:
Bibliographic Details
Published in:Cardiovasc Diabetol
Main Authors: Husain, Mansoor, Bain, Stephen C., Holst, Anders Gaarsdal, Mark, Thomas, Rasmussen, Søren, Lingvay, Ildiko
Format: Artigo
Language:Inglês
Published: BioMed Central 2020
Subjects:
Original Investigation
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC7526237/
https://ncbi.nlm.nih.gov/pubmed/32998732
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12933-020-01106-4
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items